patent/IL-176631-A0

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IL-176631-A0

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D285-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D265-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-536 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-549 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D265-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D285-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-02
filingDate	2006-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate	2006-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	IL-176631-A0
titleOfInvention	1-benzyl-5-piperazin-1-yl-3,4-dihydro-1h-quinazolin-2-one derivatives and the respective 1h-benzo (1,2,6) thiadiazine-2,2-dioxide and 1,4-dihydro- benzo(d) (1,3) oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-ht) for the treatment of diseases of the central nervous system
priorityDate	2004-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25786 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415713360 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420151483 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11404485 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID20528192 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420230187

Total number of triples: 40.